CPRX - This Under-the-Radar Pharma Company's Recent Success Is Just the Beginning
For under-the-radar companies, it's important to make sure any positive news finds its way to the eyes or ears of investors. The first quarter of 2021 is evidence of that for one small player dedicated to treating rare diseases in the pharmaceutical market. Catalyst Pharmaceuticals (NASDAQ: CPRX) recently announced strong year-end results and followed that up with an announcement related to a stock repurchase program in March, which, when combined, should get that desired attention from investors.
Image Source: Getty Images
More than five years after securing the marketing rights for the drug Firdapse to treat adults suffering from Lambert-Eaton myasthenic syndrome (LEMS) -- a rare disease that impacts the signals sent between nerves and muscles, resulting in muscle weakness -- Catalyst submitted a new drug application and received approval from the U.S. Food and Drug Administration (FDA) in 2018. By 2020, the company started seeing incremental improvements in revenue as well as earnings.
For further details see:
This Under-the-Radar Pharma Company's Recent Success Is Just the Beginning